Investigating pY240‐PTEN:Ki‐67 Interaction and its Role in DNA Damage Response

Brandon C. Jones,F. Furnari

DOI: https://doi.org/10.1096/FASEBJ.2021.35.S1.04474

2021-05-01

The FASEB Journal

Abstract:Glioblastoma (GBM) is the most aggressive and common malignant primary brain tumor. Standard of care for GBM patients involves chemotherapy and ionizing radiation which induce DNA damage to kill tumor cells; however resistance to these treatment modalities commonly develop through various mechanisms. One novel mechanism of radioresistance identified in the Furnari lab is through enhanced homologous recombination DNA damage response mediated by nuclear‐localized tyrosine‐phosphorylated PTEN (pY240‐PTEN) recruited to chromatin through interaction with the PP1 Binding Domain (PP1BD) of Ki‐67. The objective of this study is to characterize the regulation and molecular interactions involved in pY240‐PTEN and Ki‐67 binding. Biotin‐tagged synthetic peptides based on the Ki‐67 PP1BD are being used in streptavidin pull down experiments to interrogate the critical amino acids required for pY240‐PTEN:Ki‐67 interaction. Orthogonally, a minigene expressing the Ki‐67 PP1BD and Leucine‐Rich Repeat domain (required for tethering to chromatin) fused to a C‐terminal mNeonGreen is employed in glioma stem‐like cell lines to interrogate the impact of specific amino acid mutations on PTEN:Ki‐67 interaction and subsequent disruption of pY240‐PTEN mediated DNA damage response. Since phosphorylation of the PP1BD has been shown to affect binding of Ki‐67 to other phosphatases, namely PP1γ, the peptides and minigene construct will additionally be used to investigate how phosphorylation of the PP1BD can affect PTEN:Ki‐67 interactions. Specifically, phosphorylation of the Ki‐67 PP1BD by Aurora B Kinase and Cyclin‐Dependent Kinase 1 will be investigated through phosphorylated synthetic peptides and minigene constructs harboring mutations of candidate residues to non‐phosphorylatable alanine, or phosphomimetic glutamic acid or aspartic acid. The insight into this interaction will be leveraged in future studies to evaluate competitor peptides based on Ki‐67 for their ability to disrupt this binding and sensitize cells to radiation, as well as to guide CRISPR/Cas9 Ki‐67 knockin mutations to determine the effects of Ki‐67 mutation in vivo.

Chemistry,Medicine,Biology